Eli Lilly and Company
LLY · Healthcare · Pharmaceuticals
Updated 24 min ago · data delayed ≥15 min
IconicScore
ProprietaryRanked #10 of 500 by Iconic Score · #1 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.
Get the free morning email
The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →
Price performance
Export history · AnalystThis insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.
Upgrade to AnalystThis is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.
Upgrade to EnterpriseIconic Profile
Eli Lilly and Co (LLY) is a leading global pharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including diabetes, oncology, immunology, and neurodegeneration. With a market capitalization of $1119.3 billion, Lilly holds a strong position in the healthcare sector, driven by its robust pipeline of new drugs and a commitment to research and development. The company is recognized for its significant contributions to improving patient outcomes and addressing unmet medical needs, making it a key player in the pharmaceutical industry. Lilly's strategic focus on biopharmaceuticals and personalized medicine underscores its relevance in a rapidly evolving healthcare landscape, as it seeks to enhance the quality of life for patients worldwide.
IconicOracleAI™ Brief
Eli Lilly and Co (LLY) currently holds an Iconic Score of 76, supported by strong revenue growth of 48% despite falling prices, which has positively influenced brand perception. The company's high brand-visibility signal of 85/100 reflects effective logo recognition, contributing to its market presence. Recent discussions around competitive positioning in the pharmaceutical sector, particularly in relation to other major players like Johnson & Johnson and Bristol Myers Squibb, highlight the ongoing market dynamics impacting sentiment around Eli Lilly.
AI-generated explanation of current score drivers. Not investment advice.
Enterprise tier: claim your logo to manage how your brand is represented.